Introduction
During the second global PROstart workshop, Dr Richard Valicenti presented the current situation analysis for the management of locally advanced prostate cancer. Delegates were then given the opportunity to debate relevant issues in a multidisciplinary, international breakout group. As a group, the delegates developed consensus views based on their opinions of how locally advanced prostate cancer should be treated.
Management of locally advanced prostate cancer: the current situation
Key points for consideration, with regard to the management of locally advanced prostate cancer, include the fact that this stage of disease is associated with a high risk of subclinical nodal and distant metastases and is generally not curable with radical prostatectomy or radiotherapy alone. Consequently, the primary goal of treatment is disease control and avoidance of symptoms.
There are three important questions: which therapy to give; for how long; and what are the advantages of giving early therapy? Watchful waiting is rarely recommended for men with locally advanced disease, as there is a risk of disease progression and patients are likely to be symptomatic. Possible treatment options for locally advanced prostate cancer include hormone therapy, radiotherapy, or the combination of these two treatment modalities.
One form of hormone therapy involves castration, either through surgery or with a luteinizing hormonereleasing hormone agonist (LH-RHa). Another option is non-steroidal antiandrogen monotherapy with, for example, bicalutamide ('Casodex' { ). In two studies that compared bicalutamide 150 mg with castration in patients with locally advanced prostate cancer, there was no statistically significant difference between the two treatments in terms of overall survival, but bicalutamide 150 mg was associated with statistically significant benefits in quality of life compared with castration. 1 Furthermore, bicalutamide 150 mg was administered as a convenient once-daily tablet and was well tolerated. Maximal androgen blockade, commonly comprising the combination of a LH-RHa with an antiandrogen, is a further possibility for treatment in these patients. 2 Nakashima et al showed that downsizing, and occasionally downstaging of the carcinoma may occur after hormone therapy (LH-RHa alone or in combination with an antiandrogen) in patients with prostate cancer. 3 In a study of 48 patients with histologically confirmed prostate cancer, the volumes of the prostate gland, the carcinoma and the non-carcinomatous components were reduced to 60.2, 25.5 and 83.2% of their pre-treatment volumes, respectively, after 4 months' hormone therapy. This study also indicated that the androgen sensitivity of the prostate carcinoma tissue was relatively high compared with the non-cancerous prostate gland.
With regard to radiotherapy, newer techniques, such as intensity-modulated radiotherapy, avoid the rectum and the bladder and are associated with reduced toxicity compared with standard three-dimensional conformal radiotherapy. 4 Brachytherapy involves the insertion of radioactive seeds into the prostate 5 and, when used as a monotherapy, results in good outcomes if disease is localized. Comparison of the adverse effects associated with external-beam radiotherapy (EBXRT) and brachytherapy showed that there was a greater risk of urinary symptoms following brachytherapy, although EBXRT caused more gastrointestinal effects. Sexual function following treatment was similar for the two techniques after 3 -5 y. However, radiotherapy alone was associated with a high risk of relapse, particularly for those patients with high Gleason scores and prostate-specific antigen (PSA) levels > 4 ng/ml; outcomes may be improved by the combination of radiotherapy with hormone therapy as outlined below.
A number of major, randomized trials have reported improvements in disease-free and overall survival, supporting the use of androgen ablation as neoadjuvant or adjuvant therapy to EBXRT, compared with radiotherapy alone. 6 -8 For example, patients receiving radiotherapy plus immediate treatment with goserelin ('Zoladex') for 3 y had significantly better overall survival than those receiving radiotherapy alone ( Figure 1 ). 6, 9 Furthermore, the proportion of surviving patients who were diseasefree at 5 y was 85% in the combined treatment group, compared with 48% in the radiotherapy alone group (P < 0.001).
Lawton et al reported results from the Radiation Therapy Oncology Group (RTOG) trial 85-31, which evaluated the potential benefit of long-term adjuvant goserelin initiated at relapse in prostate cancer patients treated with radiotherapy. 7 For the subset of patients with Gleason score 8 -10 who did not undergo radical prostatectomy, there was a statistically significant improvement in overall (P ¼ 0.036) and cause-specific survival (P ¼ 0.019) for those patients receiving adjuvant hormones, compared with those in the radiotherapy alone arm.
In RTOG trial 86-10, patients with locally advanced prostate cancer were randomized to receive goserelin and flutamide for 2 months before and during radiotherapy (arm I) or radiotherapy alone (arm II). 8 At 8 y, significant improvements for arm I over arm II were seen in local control, incidence of distant metastases, disease-free survival, biochemical disease-free survival and cause-specific mortality (Table 1 ). 10 This benefit was also observed in a subgroup of patients (n ¼ 1358) who received bicalutamide 150 mg as adjuvant to radiotherapy. 11 Longer follow-up is underway to determine whether there is a corresponding benefit in overall survival. 10 Together, these data support the use of radiotherapy with neoadjuvant/adjuvant hormone therapy for the treatment of locally advanced prostate cancer.
Reaching a consensus on treating locally advanced prostate cancer
During the breakout session, 'The value of treating locally advanced prostate cancer', delegates from around the world discussed two case studies presented in a roleplay format.
Patient profile 1
Patient 1 was a 59-y-old man with T3b Nx prostate cancer, a Gleason score of 5 and a PSA level of 19.2 ng/ml, who had experienced mild urinary hesitancy. He was married and was keen to retain sexual potency.
Patient profile 2
Patient 2 was a 72-y-old man with T4 Nx prostate cancer, a Gleason score of 7 and a PSA level of 46 ng/ml. He had experienced lower urinary tract symptoms and back pain, but otherwise was in good health.
Making treatment recommendations
For both patient profiles, the delegates considered what the goal was for the patient, whether it be survival, palliation, or delayed progression. Different treatment options and their advantages and disadvantages were discussed, and the delegates debated which factors they felt were most important in deciding which therapy to choose. The group also discussed the literature and their individual clinical experiences, and debated a number of issues, which fell into three categories: disease-, patient-and treatmentrelated. Particular points for consideration were: the importance of PSA level, Gleason score, and clinical stage in determining risk category; the age and life expectancy of the patient; taking into account the patient's expressed wishes; and the effects of treatment on quality of life.
On the basis that the patients in the case studies did not have localized prostate cancer, there was general agreement that neither was eligible for watchful waiting or radical prostatectomy. The group felt that patient 1, the 59-y-old man keen to retain sexual potency, should receive radiotherapy, together with some form of hormone therapy. The group agreed that neoadjuvant hormone therapy should be administered prior to radiotherapy, although there were mixed views on the duration of neoadjuvant treatment and whether or not adjuvant hormone therapy should be given. One suggestion was that PSA levels should be monitored following radiotherapy, before a decision on whether or not to give adjuvant hormone therapy was made. The group discussed the advantages of radiotherapy, which was considered to be less invasive than surgery, enabled locoregional treatment, and was convenient for the patient (since treatment was for 5 days per week for 8 weeks, with no treatment at weekends). It was suggested that newer radiotherapy techniques, such as three-dimensional conformal radiotherapy, may give better results than more conventional methods since higher doses are used. It was noted that radiotherapy was associated with toxicity, which commonly includes erectile dysfunction, diarrhea, proctitis and cystitis.
The group recommended hormone therapy for patient 2, the patient with poor prognostic factors, due to the likely presence of distant metastases. However, differing views were raised by the delegates on whether or not radiotherapy should also form part of the patient's treatment. It was felt that long-term treatment with hormone therapy alone would have the potential to treat subclinical distant metastases in this patient, and would be associated with less morbidity than treatment with radiotherapy. However, hormone therapy alone would not have any effect on those cells that were hormone-insensitive; these cells would be allowed to proliferate and, in time, could dominate. As a result, some delegates favored the use of radiotherapy in addition to hormone therapy, despite possible short-term aggravation of symptoms.
The consensus views
This group commented that patients may be divided into risk categories that predict the risk of subclinical metastases, based on PSA level, Gleason score, and tumor stage; these categories determine the type and duration of treatment. The following consensus views were reached:
Hormone therapy is a recommended component of disease management and may improve survival. Radiotherapy should be combined with neoadjuvant and/or adjuvant hormone therapy.
Summary
It is clear that patients diagnosed with locally advanced prostate cancer have a range of different tumors, with different risk factors based on PSA level, Gleason score and tumor stage; these risk factors determine the type of treatment that is recommended. With this caveat, there was general agreement by the delegates that radiotherapy in combination with some form of hormone therapy should form the basis of treatment for these patients.
